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           The gene   MCOLN1  , coding for transient re-
ceptor potential  –  mucolipin-1 (TRP-ML1), is 
mutated in the rare lysosomal storage disorder 
mucolipidosis type IV (MLIV) (  1  –  4  ), which is 
clinically characterized by severe developmen-
tal delays and psychomotor retardation, consti-
tutive achlorohydria, and retinal degeneration 
and corneal opacities (  5  –  8  ). As in all lysosomal 
storage disorders, MLIV is characterized at the 
cellular level by the buildup of membranous 
and electron-dense organelles containing un-
digested lipid products (  9, 10  ). However, the 
stored lipid products are more heterogeneous 
than in most storage disorders and include 
gangliosides, sphingolipids, phospholipids, acidic 
mucopolysaccharides, and cholesterol (  11  –  14  ). 
Lipid accumulations in other lysosomal storage 
disorders are a result of the abnormal target-
ing and/or activity of individual hydrolases 
involved in lipid processing. Although which 
lipid products accumulate in MLIV have been 
identifi  ed, there is no clear consensus as to which 
enzyme activities are compromised. A previous 
report suggested that there is defi  cient ganglio-
side sialidase activity associated with MLIV (  15  ), 
whereas others argued against this enzyme de-
fi  ciency (  12, 16  ). Although some reports dem-
onstrate that both phospholipase (  17  ) and acid 
lipase (  18  ) activities are normal in MLIV pa-
tient cells, other data suggest defi  cits in activ-
ities of these enzymes in MLIV cells (  13  ). It is 
possible that such diff  erences refl  ect variations 
between the primary fi  broblasts used in these 
studies or compensatory changes in enzyme ac-
tivity at the gene expression level. 
  Both immunofl  uorescence and subcellular 
fractionation studies demonstrate that TRP-
ML1 is localized to lysosomes (  19  –  22  ), and it is 
thought that lipid accumulations associated with 
MLIV are a result of imbalanced ion homeosta-
sis along the endocytic pathway resulting from 
TRP-ML1 dysfunction (  8, 12, 23  ). A consensus 
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    The lysosomal storage disorder mucolipidosis type IV (MLIV) is caused by mutations in the 
transient receptor potential  –  mucolipin-1 (TRP-ML1) ion channel. The   “  biogenesis  ”   model 
for MLIV pathogenesis suggests that TRP-ML1 modulates postendocytic delivery to lyso-
somes by regulating interactions between late endosomes and lysosomes. This model is 
based on observed lipid traffi  cking delays in MLIV patient fi  broblasts. Because membrane 
traffi  c aberrations may be secondary to lipid buildup in chronically TRP-ML1  –  defi  cient 
cells, we depleted TRP-ML1 in HeLa cells using small interfering RNA and examined the 
effects on cell morphology and postendocytic traffi  c. TRP-ML1 knockdown induced gradual 
accumulation of membranous inclusions and, thus, represents a good model in which to 
examine the direct effects of acute TRP-ML1 defi  ciency on membrane traffi  c. Ratiometric 
imaging revealed decreased lysosomal pH in TRP-ML1  –  defi  cient cells, suggesting a disrup-
tion in lysosomal function. Nevertheless, we found no effect of TRP-ML1 knockdown on 
the kinetics of protein or lipid delivery to lysosomes. In contrast, by comparing degradation 
kinetics of low density lipoprotein constituents, we confi  rmed a selective defect in choles-
terol but not apolipoprotein B hydrolysis in MLIV fi  broblasts. We hypothesize that the 
effects of TRP-ML1 loss on hydrolytic activity have a cumulative effect on lysosome func-
tion, resulting in a lag between TRP-ML1 loss and full manifestation of MLIV. 1478 MEMBRANE TRAFFIC AND TURNOVER IN TRP-ML1  –  DEFICIENT CELLS   | Miedel et al. 
TRP-ML1  –  defi  cient fi  broblasts. It is possible that the buildup 
of lipids and other undigested materials in these cells even-
tually impedes the entry of traffi   cking markers into lyso-
somes and manifests as delays in membrane traffi   c. Indeed, 
exactly the same lipid traffi   c delays were reported in several 
lysosomal storage disorders, whose main causes are entirely 
metabolic and are not directly related to membrane traffi   c 
(GM1 and GM2 gangliosidoses, Fabry  ’  s disease, and Niemann-
Pick types A or B) (  8, 38  ). To circumvent this issue, we used 
an siRNA approach to examine the consequences of acute 
down-regulation of TRP-ML1 function on postendocytic 
delivery to lysosomes. 
  Understanding whether TRP-ML1 regulates membrane 
traffi   c or lipolysis is a key step in determining whether enzyme 
replacement therapies will be eff  ective as treatment for MLIV. 
A fi  nding that TRP-ML1 directly regulates membrane traffi   c 
will make it unlikely that enzyme replacement therapies for 
MLIV will succeed. If, however, TRP-ML1 regulates lysosomal 
ion homeostasis, then replacement therapies, perhaps based on 
enzymes modifi  ed to work in an MLIV-specifi  c lysosomal 
environment, are likely to be useful. 
    RESULTS   
  siRNA-mediated TRP-ML1 knockdown 
  We identifi   ed two siRNA oligonucleotides specifi  c  for 
TRP-ML1 and tested their ability to knock down endog-
enous as well as heterologously expressed hemagglutinin 
(HA) epitope  –  tagged TRP-ML1 in HeLa cells. Cells were 
transfected with control (nonsilencing) or with one of two 
TRP-ML1  –  specifi  c siRNA oligonucleotides. Cells were har-
vested 24 h after transfection and subjected to Western blot 
analysis. We previously demonstrated that the 65-kD full-
length TRP-ML1 is intracellularly cleaved into two frag-
ments of roughly equal molecular mass (40 and 37 kD) (  19, 20  ). 
Because it contains only a single transmembrane domain, 
the N-terminal fragment is less prone to aggregation than the 
full-length protein or C-terminal half, and is thus easier to 
detect upon SDS-PAGE. The arrowhead in   Fig. 1 A   marks 
the migration of the N-terminal fragment of TRP-ML1.   
Transfection with either of the TRP-ML1  –  specifi  c siRNA 
duplexes resulted in virtually complete knockout of native 
TRP-ML1. Similarly, knockdown of exogenously expressed 
TRP-ML1 was observed when cells transfected with siRNA 
were later retransfected with an HA-tagged version of TRP-
ML1 (  Fig. 1 B  ). Under these overexpression conditions, 
we could detect both the full-length protein and the HA-
tagged cleaved fragments on Western blots of cells transfected 
with control but not with TRP-ML1  –  specifi  c siRNA duplexes 
(  Fig. 1 B  ). 
  We next optimized conditions to knock down TRP-
ML1 over longer time periods. To determine the duration of 
TRP-ML1 knockdown, cells were harvested for Western 
blot analysis at 1, 3, or 5 d after transfection with either a 
nonsilencing control siRNA duplex or with TRP-ML1  –  spe-
cifi  c oligonucleotides. As before, knockdown was virtually com-
plete within 1 d of transfection; however, native TRP-ML1 
on TRP-ML1 permeability characteristics is only beginning 
to emerge, whereas native TRP-ML1 activity has not been 
studied. Recombinant TRP-ML1 was characterized in the 
plasma membrane, where it is targeted under overexpression 
conditions (  19, 24  ), and in artifi  cial lipid bilayers using TRP-
ML1 purifi  ed from overexpressing cells or synthesized in a 
cell-free system (  25, 26  ). These experimental systems yielded 
outwardly rectifying monovalent cation-permeable channels. 
On the other hand,   “  activating  ”   mutations in TRP-ML1 
resulted in an inwardly rectifying current (  27  ). Such mu-
tants were permeable to Ca  2+  , which is similar to some 
previously published data on wild-type TRP-ML1 (  24, 28  ), 
whereas other studies have demonstrated a Ca  2+   block of 
TRP-ML1 (  13, 26  ). 
  The   “  biogenesis  ”   model for MLIV progression suggests 
that TRP-ML1 regulates lipid traffi   cking by mediating spe-
cifi  c fi  ssion and/or fusion events between late endosomes and 
lysosomes that occur during the process of lysosome biogen-
esis, a Ca  2+  -dependent process (  29  –  34  ). In the absence of 
functional TRP-ML1, endocytosed material destined for 
degradation accumulates because of impaired access to the 
hydrolases necessary for catabolism. Moreover, this model 
predicts that there will be a global defect in the postendocytic 
delivery of both lipids and proteins to lysosomes. The notion 
that TRP-ML1 directly regulates membrane traffi   c is based 
on the observations that TRP-ML1  –  defi  cient cells display 
aberrant mixing of lysosomal and endosomal content (  28, 33  ) 
and that traffi   cking of a fl  uorescent conjugate of BODIPY-
C5-lactosylceramide (LacCer) along the endocytic pathway 
is delayed in these cells (  13, 21, 23  ). This model is also sup-
ported by studies performed in   Caenorhabditis elegans   in which 
the functional TRP-ML1 orthologue CUP-5 has been iden-
tifi  ed (  35, 36  ). Knockout of the   cup-5   gene has been associ-
ated with defects in lysosome biogenesis. There is increased 
colocalization of late endosomal and lysosomal markers in 
  cup-5   mutants, and loss of this gene results in the abnormal 
accumulation of vacuolar structures that are interpreted to 
represent hybrid late endosomal  –  lysosomal structures (  33  ). 
Again, the observed endocytic abnormalities observed in   cup-5   
mutants were alleviated by exogenous expression of func-
tional human TRP-ML1. 
  The   “  metabolic  ”   model suggests that, similar to the ClC 
channels, TRP-ML1 regulates lysosomal ion homeostasis and 
thus directly aff  ects the activity of lysosomal digestive enzymes 
(  37  ). It was hypothesized that TRP-ML1 functions as a H  +   
leak pathway to prevent the overacidifi  cation of the lysosomal 
lumen, and that the activity of lysosomal lipases are disrupted as 
a consequence of the ionic imbalance in TRP-ML1  –  defi  cient 
lysosomes (  13  ). 
  An additional complexity that must be clarifi  ed to prop-
erly describe MLIV pathogenesis and TRP-ML1 function is 
whether any defects in membrane traffi   c or lipid metabo-
lism are the primary cause of MLIV, or are instead second-
ary eff  ects caused by the chronic accumulation of undigested 
lipids in these cells. The membrane traffi   cking studies dis-
cussed earlier in this section were performed in chronically JEM VOL. 205, June 9, 2008 
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gressive accumulation of pleomorphic inclusions scattered 
throughout the cytoplasm of cells transfected with TRP-
ML1 siRNA, whereas very few such inclusions were observed 
in control cells (  Fig. 2 A  ).   These inclusions are reminiscent of 
those observed in patient-derived MLIV fi  broblasts, some of 
which contain multilamellar membranes, whereas others are 
fi  lled with electron-dense, gray material (  Fig. 2 B  ). Quantita-
tion of the accumulation of storage bodies in both control 
and TRP-ML1 siRNA  –  transfected cells is shown in   Fig. 2 C  . 
In TRP-ML1 siRNA  –  treated cells, inclusions begin to accu-
mulate as early as 1 d after siRNA transfection and gradually 
increased over the 5-d period. It should be noted that even 
after 12 d of siRNA treatment, the mean number of inclusions 
observed in HeLa cells (69 inclusions per cell slice;   Fig. 2 C  ) 
was much lower than that previously determined for MLIV 
fi  broblasts using the same method (    720 inclusions per cell 
slice;   Fig. 2 C  ). 
  To confi  rm that the accumulation of storage bodies in 
TRP-ML1 siRNA  –  treated cells is a direct consequence of 
TRP-ML1 loss, we performed knock-in experiments in which 
the TRP-ML1 siRNA  –  treated cells were transfected with an 
HA-tagged siRNA-resistant TRP-ML1 construct (HA-ML1  R  ). 
Because transfection with cDNA was only     30% effi   cient 
in these cells, we cotransfected them with GFP-expressing 
plasmid and, the following day, enriched for GFP-expressing 
cells using FACS. The cells were then transfected with TRP-
ML1  –  specific siRNA oligonucleotides and processed for 
electron microscopic analysis 48 h later. Knockdown of endog-
enous TRP-ML1 knockdown and expression of the siRNA-
resistant HA-ML1  R   construct were confi  rmed by Western 
blotting of duplicate samples (  Fig. 2 D  ). As shown in   Fig. 2 E  , 
siRNA-treated cells expressing HA-ML1  R   displayed a marked 
decrease in the number of inclusions compared with TRP-
ML1 knockdown cells that were not transfected with cDNA, 
suggesting that HA-ML1  R   expression rescues or prevents in-
clusion formation in TRP-ML1  –  defi  cient cells. These stud-
ies confi  rm that inclusion formation is TRP-ML1 specifi  c. 
Thus, this experimental system represents an appropriate 
model in which to study the early stages of MLIV progres-
sion. As a result, this approach will enable us to assess the 
function of TRP-ML1 under conditions that are unbiased by 
the chronic accumulation of undigested lipid material that 
may itself have adverse eff  ects on specifi  c lipid and protein 
traffi   cking events. 
  Lipid inclusions in TRP-ML1  –  defi  cient cells are 
lamp-1 positive and receive endocytosed cargo 
  To examine whether the inclusions that accumulate in TRP-
ML1  –  defi  cient cells represent active components of the en-
docytic pathway, control and 5-d TRP-ML1 siRNA  –  treated 
cells were labeled en bloc with antibodies directed against the 
lysosomal membrane protein lamp-1, and were subsequently 
labeled with biotinylated secondary antibodies. Immunoreac-
tivity was detected using avidin  –  biotin peroxidase complex 
and 3,3    -diaminobenzidine.   Fig. 3 A   (right) shows that inclu-
sions from TRP-ML1  –  defi  cient cells are positive for lamp-1 
reappeared within 3 d after the initial siRNA duplex trans-
fection (  Fig. 1 C  , top). To overcome this, we performed a 
similar experiment except that the 3- and 5-d samples were 
retransfected with TRP-ML1  –  specifi  c or control siRNA 
duplexes 48 h after the initial transfection, and were sub-
sequently harvested for Western blot analysis at 3 or 5 d. 
As shown in   Fig. 1 C   (bottom), using these conditions, we 
were able to knock down TRP-ML1 almost completely dur-
ing this time course. 
  With specifi  c TRP-ML1 knockdown conditions in place, 
we next sought to determine the onset of MLIV-like lipid 
inclusion formation over a 5-d knockdown period in HeLa 
cells. Electron microscopic analysis of cells transfected with 
either control or TRP-ML1  –  specifi  c siRNA revealed the pro-
    Figure 1.         siRNA-mediated knockdown of TRP-ML1.   (A) HeLa cells 
were transfected with either nonsilencing control or TRP-ML1  –  specifi  c 
siRNA oligonucleotides. Cells were harvested for Western blot analysis after 
24 h. Equal amounts of total protein were loaded for SDS-PAGE, as deter-
mined by protein assay. Samples were transferred to nitrocellulose and 
immunoblotted to detect endogenous levels of TRP-ML1 using an antibody 
directed against the fi  rst extracellular loop of the protein. The arrowhead 
denotes the migration of the cleaved form of TRP-ML1. (B) HeLa cells were 
transiently transfected with cDNA encoding HA epitope  –  tagged TRP-ML1 
24 h after initial transfection with either control or TRP-ML1  –  specifi  c 
siRNA duplexes. After an additional 24-h incubation, cells were solubilized 
and equal amounts of total protein were immunoprecipitated using anti-
HA antibodies. After SDS-PAGE, proteins were transferred to nitrocellulose 
and probed using horseradish peroxidase  –  conjugated anti-HA antibody. 
10% of the cell lysate was saved before immunoprecipitation and immuno-
blotted using antitubulin antibody as an additional loading control (bot-
tom). (C) HeLa cells were transfected with either nonsilencing control or 
TRP-ML1 – specifi  c siRNA oligonucleotides and were harvested for Western 
blot analysis 1, 3, or 5 d after transfection (top), or were retransfected with 
siRNA duplexes after 2 d and were harvested for Western analysis at 3 or 5 d 
(bottom). Samples were subjected to SDS-PAGE, transferred to nitrocel-
lulose, and immunoblotted to detect endogenous TRP-ML1. The migration 
of molecular mass markers (in kD) is noted on the left of the blots.     1480 MEMBRANE TRAFFIC AND TURNOVER IN TRP-ML1  –  DEFICIENT CELLS   | Miedel et al. 
(  Fig. 4 B  , right). These results demonstrate that the observed 
lipid inclusions are not   “  dead-end  ”   structures but are able to 
receive material internalized along the endocytic pathway. 
  Lysosomal pH is reduced upon siRNA-mediated knockdown 
of TRP-ML1 
  Previous studies examining the measurement of lysosomal 
pH in TRP-ML1  –  defi  cient cells have produced confl  icting 
results. Early studies performed using ratiometric imaging 
approaches determined that the lysosomal pH in MLIV cells 
was elevated almost one full pH unit higher when compared 
with control cells or to cells isolated from patients with other 
lysosomal storage diseases (  39  ). In other studies, lysosomal 
pH in MLIV cells has been reported to be either more acidic 
(  13  ) or unchanged (  21, 40  ) compared with control cells. 
(dark stain identifi  ed by arrowheads).   In contrast, lamp-1  –  pos-
itive compartments in cells transfected with a control siRNA 
duplex were smaller and more uniformly stained (  Fig. 3 A  , 
middle and left). This staining pattern is consistent with the 
idea that the lipid inclusions in TRP-ML1  –  defi  cient cells are 
of late endosomal or lysosomal origin. 
  We next asked whether the lipid inclusions present in 
TRP-ML1  –  defi  cient cells are accessible to internalized cargo. 
For these studies, cells transfected with TRP-ML1  –  specifi  c 
siRNA for 5 d were loaded for 6 h with albumin-conjugated 
10-nm colloidal gold particles, chased for an additional 12 h to 
allow accumulation in lysosomes, and processed for electron 
microscopy.   Fig. 4 B   (left and middle) shows extensive deliv-
ery of gold particles to lipid inclusions in TRP-ML1  –  defi  cient 
cells.   Similar results were also obtained using MLIV fi  broblasts 
    Figure 2.         Time course of lipid inclusion formation in TRP-ML  –  defi  cient cells.   (A and B) Electron micrographs of HeLa cells after either 1 or 5 d of 
TRP-ML1 – specifi  c or control siRNA oligonucleotide transfection. Bars: (A) 2   μ  m; (B, left) 200 nm; (B, right) 500 nm. (C) Quantitation of the effect of 
TRP-ML1 knockdown on the formation of storage inclusions. The number of inclusions was calculated using the automated particle counting function of 
ImageJ. Data are expressed as the number of inclusions per cell slice   ±   SEM (D) Western blot analysis of siRNA-treated cells expressing siRNA-resistant 
HA-ML1  R  . HeLa cells were transfected with either control or TRP-ML1  –  specifi  c siRNA, as indicated. 24 h after siRNA treatment, cells were cotransfected 
with plasmids encoding GFP and either HA-ML1 (non-siRNA resistant) or HA-ML1  R   (siRNA resistant). The next day, cells were sorted by FACS analysis to 
identify GFP-positive (transfected) cells and were subsequently retransfected with the appropriate siRNA and returned to culture for 48 h. Cells were 
harvested, and 30   μ  g of total protein was loaded for SDS-PAGE. Samples were transferred to nitrocellulose and immunoblotted to detect endogenous 
levels of TRP-ML1 (top), HA-ML1 or HA-ML1  R   (middle), or     -actin (bottom) as a loading control. (E) Quantitation of the effect of HA-ML1  R   expression  on 
formation of storage inclusions in TRP-ML1 siRNA  –  treated cells. The number of inclusions was calculated as described in C. The migration of molecular 
mass markers (in kD) is noted on the left of the blots.     JEM VOL. 205, June 9, 2008 
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in Materials and methods (  42  ). As shown in a representa-
tive experiment in   Fig. 4  , TRP-ML1 knockdown was as-
sociated with lysosomal acidifi  cation. In this experiment, 
the mean lysosomal pH in cells treated with control siRNA 
was 5.44   ±   0.06, whereas in cells treated with TRP-ML1  –
  specifi  c siRNA, the mean pH was estimated to be 4.04   ±   0.09. 
Over the course of four experiments using identical imaging 
conditions, the mean diff  erence in pH between control and 
TRP-ML1 siRNA  –  treated cells was 1.12   ±   0.16 pH units. 
These results indicated that loss of functional TRP-ML1 
in cells results in a reduction of lysosomal pH even after a 
short period of TRP-ML1 knockdown, and that even lyso-
somes that have not yet accumulated signifi  cant amounts 
of undigested material are functionally aff  ected by loss of 
TRP-ML1. 
  Lysosomal delivery of LacCer is unimpaired 
in TRP-ML1  –  defi  cient cells 
  Numerous studies have reported that traffi   cking of the fl  uo-
rescent lipid analogue LacCer is impaired in MLIV fi  broblasts 
as well as in primary fi  broblasts from several other lysosomal 
storage diseases (  13, 21, 23, 38  ). We thus examined whether 
TRP-ML1 knockdown cells also display this phenotype. 
HeLa cells preloaded with fl  uorescent dextran were treated 
One unifying feature in all these studies is that they were 
performed using isolated patient fi  broblasts. These cells are 
not necessarily appropriate for such experiments because of 
the long-term accumulation of undigested lipids that induce 
autofl  uorescence (  41  ), which may interfere with dye load-
ing and/or retention, and which may induce compensatory 
changes in these cells at the level of protein expression. 
Therefore, we examined lysosomal pH in cells treated with 
TRP-ML1  –  specifi  c siRNA for 5 d, allowing us to measure 
pH in TRP-ML1  –  defi  cient cells without any potential ef-
fects caused by long-term lipid accumulation. To quantita-
tively determine lysosomal pH in cells treated with control 
or TRP-ML1  –  specifi  c siRNA, cells were loaded for 12 h 
simultaneously with FITC- and tetramethylrhodamine (TMR)- 
conjugated 10-kD dextrans (3 mg/ml) to allow for accumu-
lation in lysosomes. In separate experiments, we confi  rmed 
that both dextrans traffi   cked together and localized in lyso-
somes after the specifi  ed chase period (unpublished data). 
The FITC-conjugated dextran was used as a pH indicator, 
whereas the TMR-conjugated dextran provided a pH-in-
sensitive readout for the ratiometric pH measurements. After 
dextran loading, measurements of lysosomal pH were ob-
tained by calculating the ratio of TMR/FITC fl  uorescence 
and fi  tting these to a standard curve constructed as described 
    Figure 3.         Inclusion bodies are lamp-1 positive and remain accessible to internalized cargo in TRP-ML  –  defi  cient cells.   (A) Lamp-1 immuno-
reactivity in control and TRP-ML  –  defi  cient cells is indicated by arrowheads. Control or TRP-ML1 siRNA  –  treated HeLa cells (5 d) were labeled with antibodies 
directed against the lysosomal membrane protein lamp-1, as described in Materials and methods. Lysosomes from both control and TRP-ML1 siRNA  –
  treated cells are positive for lamp-1 immunoreactivity. Arrowheads indicate lamp-1  –  positive labeled compartments. Bars: (left) 2   μ  m; (middle) 500 nm; 
(right) 500 nm. (B) Colloidal gold inside storage inclusions in TRP-ML  –  defi  cient cells. Control or TRP-ML1 siRNA  –  treated HeLa cells (5 d) were loaded with 
10-nm colloidal gold particles and processed for electron microscopy as described in Materials and methods. A large fraction of the inclusions was gold 
positive in 5-d siRNA cells, indicating that the inclusions were recently formed. Gold was chased for 16 h. Arrowheads indicate colloidal gold  –  labeled 
compartments. Bars: (left) 200 nm; (middle) 2   μ  m; (right) 500 nm.     1482 MEMBRANE TRAFFIC AND TURNOVER IN TRP-ML1  –  DEFICIENT CELLS   | Miedel et al. 
undigested lipid buildup. Therefore, we performed a series of 
experiments to quantitate the rate of protein and lipid deliv-
ery to lysosomes in control and TRP-ML1 knockdown HeLa 
cells. The premise of these experiments was that if TRP-ML1 
directly regulates the delivery of endocytosed material to ly-
sosomes, then acute TRP-ML1 down-regulation would re-
sult in prelysosomal buildup of endocytosed material, whose 
entry into lysosomes will be signifi  cantly delayed. 
    Fig. 6   shows the results of our experiments.   Control and 
siRNA-transfected cells were loaded with 2   μ  g/ml LacCer 
for 15 min at 37  °  C to incorporate LacCer into the plasma 
membrane. The cells were washed and chased for brief pe-
riods (up to 60 min) in the presence of 5 mg/ml BSA. After 
the chase, cells were loaded with LysoTracker Red to iden-
tify lysosomes, and confocal images of cells were analyzed for 
overlap between LacCer and LysoTracker Red to quantify 
lysosomal delivery of LacCer. As shown in   Fig. 6  , we found 
no diff  erence in kinetics of lysosomal delivery of LacCer in 
control versus TRP-ML1  –  defi  cient cells. As a positive con-
trol, we pharmacologically suppressed membrane fusion and 
confi  rmed that this induces an observable delay in lipid traffi   c. 
To do this, we loaded untransfected HeLa cells with 1   μ  M of 
the cell-permeable Ca  2+   chelator BAPTA-AM. Because ve-
sicular fusion in the endocytic pathway requires Ca  2+  , chela-
tion with BAPTA should suppress membrane fusion and, 
thus, replicate the conditions predicted by the biogenesis model 
associated with the loss of TRP-ML1 Ca  2+   conductance. 
  Fig. 6  shows that, unlike TRP-ML1 down-regulation, BAPTA-
AM inhibited delivery of LacCer to lysosomal compartments. 
Therefore, the delivery of LacCer to lysosomes is unimpaired 
in TRP-ML1  –  defi  cient cells. 
  Low density lipoprotein (LDL) traffi  cking and degradation 
in TRP-ML1  –  defi  cient cells 
  To more quantitatively assess lysosomal delivery and func-
tion in TRP-ML1 knockdown cells, we examined the 
kinetics of lysosomal delivery, apolipoprotein B (apoB) proteol-
ysis, and cholesterol deesterifi  cation of LDL. Previous studies 
in MLIV fi  broblasts have specifi  cally probed lipid metabo-
lism along the LDL receptor  –  mediated pathway of lysosomal 
degradation using radiolabeled forms of both sphingomyelin 
and cholesteryl oleate (CO) (  18  ). These studies found that 
MLIV fi  broblasts metabolize both lipids more slowly com-
pared with control cells. Therefore, our fi  rst approach was 
to examine whether delivery of LDL to lysosomes in TRP-
ML1  –  deficient cells was impaired. To determine this, we 
used fl  uorescence microscopy to examine and quantitate the 
delivery of DiI-labeled LDL to lysosomes of HeLa cells 
transfected with TRP-ML1  –  specifi  c siRNA. In these stud-
ies, cells were treated with either control or TRP-ML1 
siRNA duplexes for 5 d. Alexa Fluor 647  –  conjugated dex-
tran was preaccumulated in lysosomes during a 12-h prein-
cubation before the start of the experiment. The following 
day, cells were incubated with 20   μ  g/ml DiI-LDL on ice for 
1 h and were subsequently chased in fresh medium for 30 or 
120 min at 37  °  C. At either time point, cells were fi  xed and 
with control or TRP-ML1 siRNA were incubated with 
LacCer for 60 min and then chased for 5 h at 37  °  C. As shown 
in   Fig. 5 A  , LacCer staining in cells transfected with a control 
siRNA oligonucleotide was tightly clustered around the 
nucleus, consistent with effi   cient delivery to the Golgi com-
plex (top).   In contrast, the LacCer staining pattern in cells 
treated with TRP-ML1  –  specifi  c siRNA was dispersed through-
out the cytoplasm and colocalized partly with preinternal-
ized dextran. These results are consistent with observations 
in MLIV fi  broblasts (unpublished data) (  13, 21, 23  ) and with 
another recent study examining TRP-ML1 knockdown in 
murine macrophages (  43  ). 
  We examined whether expression of the siRNA-resistant 
construct HA-ML1  R   in knockdown cells could rescue the 
LacCer sorting defect. Cells were cotransfected with a vector 
encoding the fl  uorescent protein mCherry (to identify trans-
fected cells) and HA-ML  R  . The following day, these cells 
were transfected with TRP-ML1 siRNA and cultured for 
48 h before labeling with LacCer as described.   Fig. 5 B   shows 
juxtanuclear localization of LacCer in mCherry-positive 
(presumably HA-ML  R    –  expressing) cells, consistent with the 
staining pattern of control cells. Therefore, siRNA-mediated 
TRP-ML1 knockdown eff  ectively recapitulates the cellular 
phenotype of MLIV cells. 
  A crucial question in MLIV pathogenesis is whether the 
delay in LacCer traffi   cking occurs at the step of endosome  –
  lysosome interaction, as predicted by the biogenesis model. 
Although our previously published data did not support this 
idea (  13  ), a detailed analysis of the membrane traffi   c in MLIV 
fi  broblasts performed by Pryor et al. (  21  ) suggested a delay in 
transfer of the endocytosed material from late endosomes to 
lysosomes. However, because these studies were performed 
in MLIV fi  broblasts, this eff  ect could be a secondary result of 
    Figure 4.         Lysosomal pH is lower in TRP-ML1 siRNA  –  treated cells.  
Control or TRP-ML1 siRNA  –  treated (5 d) HeLa cells were loaded with 
3 mg/ml of FITC- and TMR-conjugated dextrans for 12 h. Lysosomal pH 
was determined by calculating the ratio of TMR/FITC fl  uorescence. Images 
were acquired as described in Materials and methods. Ratiometric data 
were converted to absolute values of pH using TMR/FITC ratios deter-
mined from permeabilized cells equilibrated with calibration solutions. 
Data from 20 random fi  elds of cells were quantifi  ed, and the pH deter-
mined is presented as mean pH   ±   SEM. Similar results were obtained in 
four independent experiments.     JEM VOL. 205, June 9, 2008 
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  Our second approach was to examine the delivery and 
lysosomal degradation of both the lipid and protein compo-
nents of LDL in both control and MLIV fi  broblasts as well as 
in control and in TRP-ML1 siRNA  –  treated cells. If TRP-
ML1 is involved in the interactions between late endosomes 
and lysosomes, then there should be a defect in the degrada-
tion of both the protein and lipid components of LDL along 
this pathway. To monitor the degradation of the protein 
component of LDL, cells were incubated with   125  I-apoB-
LDL for 2 h on ice. After ligand binding, cells were exten-
sively washed and incubated with prewarmed medium for 
various times. At the indicated times, the medium was re-
moved and replaced, and degradation kinetics were deter-
mined by trichloroacetic acid (TCA) precipitation of the 
medium and of cell lysates solubilized at the end of the 
time course. The rate of apoB degradation was determined by 
coverslips were mounted for analysis. Delivery of DiI-LDL 
to lysosomes was measured by quantifying the percentage of 
overlap between DiI-LDL and the preloaded Alexa Fluor 647  –
  dextran expressed as the amount of Di-LDL present in dextran-
positive compartments. As shown in   Fig. 7 A  ,     60% of the 
internalized DiI-LDL colocalized with the preloaded Alexa 
Fluor 647  –  dextran by 120 min of chase in both control and 
TRP-ML1 siRNA  –  treated cells, suggesting that delivery of 
LDL in TRP-ML1  –  defi  cient cells is unimpaired.   We also 
did not observe a delay in parallel studies quantifying DiI-
LDL delivery in MLIV and MLII fi  broblasts relative to 
control cells, suggesting that chronic lipid buildup in these 
cells does not aff  ect LDL delivery to lysosomes (  Fig. 7 B  ). 
Collectively, these results suggest that delivery of LDL to ly-
sosomes is unaff  ected by both acute and chronic loss of 
TRP-  ML1 function. 
    Figure 5.         Postlysosomal lipid traffi  c is impaired in TRP-ML  –  defi  cient cells.   (A) Control or TRP-ML1 siRNA  –  treated (5 d) HeLa cells were pre-
loaded for 12 h with Alexa Fluor 647  –  conjugated dextran. The next day, cells were labeled with LacCer, as described in Materials and methods, and 
chased for 5 h. Fluorescence images of both LacCer (green) and Alexa Fluor 647  –  dextran (red) were obtained for both control (top) and TRP-ML1 
siRNA  –  treated (bottom) cells. Bar, 10   μ  m. (B) LacCer Golgi localization can be restored by expression of HA-ML1  R   in  TRP-ML1  siRNA – treated  cells. 
TRP-ML1 siRNA  –  treated cells (2 d) were cotransfected with plasmids encoding the siRNA-resistant construct HA-ML  R   cDNA and the fl  uorescent pro-
tein mCherry (to identify DNA-transfected cells) 24 h before siRNA treatment. Cells were loaded and chased with LacCer as in A. The juxtanuclear 
LacCer staining pattern reminiscent of normal cells is observed in mCherry-positive cells but not in neighboring cells that presumably do not express 
HA-ML1  R .  Bar,  10   μ M.   1484 MEMBRANE TRAFFIC AND TURNOVER IN TRP-ML1  –  DEFICIENT CELLS   | Miedel et al. 
include cargo binding and entry, receptor  –  ligand dissociation, 
membrane fusion, degradation of internalized lipids, proteins, 
and carbohydrates, and excretion of digested products through 
the lysosomal membrane (  45, 46  ). The effi   ciency of these 
processes depends on the maintenance of specifi  c ionic envi-
ronments that are established by the combination actions of 
ion channels and pumps residing in endocytic compartments 
(  32, 47  ). New information about these ion transporters regu-
larly emerges from studies on the genetic determinants of lyso-
somal storage diseases. MLIV is one of several examples of 
lysosomal storage diseases caused by a dysfunction in the ionic 
balance of the endocytic machinery. The severity of this dis-
ease is compounded by the fact that no unifi  ed model exists 
for MLIV pathogenesis, thus hindering the development of 
pharmacological interventions. 
  Because the identifi  cation that mutations in the  MCOLN1   
gene are responsible for the MLIV disease phenotype (  1  ), it 
has become apparent that this lysosomal cation channel plays 
a key role in the maintenance and regulation of postendo-
cytic events (  5, 12, 18, 23  ). As described in the Introduction, 
two models exist to explain the primary defect in MLIV. The 
biogenesis model suggests that MLIV is caused by delayed 
membrane traffi   c to lysosomes as a result of impaired endosome  –
  lysosome fusion or fi  ssion (  21, 31, 33, 34  ). The metabolic 
model postulates that MLIV results from an ionic imbalance 
in lysosomes that precludes effi   cient processing of internalized 
lipids and other molecules (  13  ). 
  In principle, a comprehensive model for the regulation of 
TRP-ML1 channel activity would enable the discrimination 
between these models. Fusion between various membrane-
bound vesicular endocytic compartments is regulated by Ca  2+   
concentration in the vicinity of these compartments, whereas 
the traffi   cking and activity of various proteases and lipases de-
pends on the acidic environment maintained within both en-
dosomal and lysosomal compartments (  32, 47  ). TRP-ML1 
has been reported to be permeable to both Ca  2+   and to H  +  ; 
calculating the cumulative release of TCA-soluble counts 
into the medium. As shown in   Fig. 8 A  , the kinetics of deg-
radation of apoB were identical in both control and TRP-
ML1  –  defi  cient cells, as well as in control and MLIV fi  broblasts.   
Similarly, we found no diff  erence in the kinetics of   125  I-trans-
ferrin recycling in MLIV and control fi  broblasts, or in the 
degradation of   125  I  –  epidermal growth factor in both siRNA-
treated cells and MLIV fi  broblasts (unpublished data). These 
results suggest that there is no defect in postendocytic re-
cycling or lysosomal delivery in TRP-ML1  –  defi  cient cells. 
These results are consistent with the observations of Chen et 
al., who (using a similar   125  I-transferrin recycling assay) also 
found no defects in the endocytosis or recycling of transferrin 
in MLIV fi  broblasts (  23  ). 
  To examine the degradation of the lipid component of 
LDL, we used an experimental approach previously used by 
Groener et al. (  44  ) to monitor the metabolism of radiolabeled 
CO. Cells were incubated with [  14  C]CO in complex with LDL 
for 4.5 h at 37  °  C. After labeling, cells were incubated for various 
times with prewarmed medium supplemented with lipopro-
tein-defi  cient serum (LPDS). At each time point, the medium 
was removed and replaced, and degradation kinetics were deter-
mined by quantitating the cumulative release of free fatty acids 
into the cell-culture medium compared with the amount that 
remained cell associated. As shown in   Fig. 8 B  , the kinetics of 
[  14  C]CO degradation were not diff  erent in cells treated with ei-
ther control or TRP-ML1  –  specifi  c siRNA for 5 d. Addition-
ally, treatment with TRP-ML1  –  specifi  c siRNA over a 12-d 
period also had no eff  ect on cholesterol hydrolysis (unpublished 
data). However, the rate of [  14  C]CO degradation in MLIV fi  -
broblasts was signifi  cantly slower when compared with the rates 
of degradation in either control or MLII fi  broblasts. 
    DISCUSSION   
  The internalization and processing of cargo via the endocytic 
pathway is a complex process involving numerous steps that 
    Figure 6.         Lysosomal delivery of LacCer is normal in TRP-ML1 siRNA  –  treated cells.   (A) Control and TRP-ML1 siRNA  –  treated cells were loaded with 
2   μ  g/ml LacCer for 15 min at 37  °  C and LysoTracker Red to label lysosomes, as described in Materials and methods. Bar, 10   μ  m. (B) Where indicated, cells 
were incubated with 10   μ  M BAPTA-AM for 1 h. Delivery of LacCer to lysosomes was measured by quantifying the percent overlap between LacCer and 
LysoTracker. Data are mean   ±   SEM. *, P = 0.013 (obtained in six separate measurements).     JEM VOL. 205, June 9, 2008 
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not yet chronically accumulated undigested lipids. Because 
MLIV has been unequivocally identifi  ed as a   “  single-gene dis-
order  ”  , acute TRP-ML1 knockdown using siRNA is a valid 
model for the early stages of MLIV pathogenesis. Using this 
approach, we were able to down-regulate TRP-ML1 expression 
in cells over a period of several days. During this time, lyso-
somes from these cells gradually accumulated lipid inclusions, 
but at a level signifi  cantly less than previously described in 
MLIV fi  broblasts (  13  ). Formation of inclusions was effi   ciently 
rescued by transfection of an siRNA-resistant version of 
TRP-ML1. Lipids accumulated in lamp-1  –  positive organ-
elles, suggesting that the inclusions are of lysosomal origin. 
however, electrophysiological characterization of TRP-ML1 
activity under physiological conditions has yet to be per-
formed (  13, 24  –  26, 28  ). 
  In the present studies, we sought to determine whether 
MLIV results from aberrant membrane traffi   c to lysosomes. 
An additional issue is whether any observed defects in mem-
brane traffi   cking or lipid metabolism are a primary result of 
MLIV pathophysiology, or are instead secondary eff  ects that 
result from the chronic accumulation of undigested lipids in 
TRP-ML1  –  defi  cient cells. Our goal was to design an experi-
mental system in which we could examine these membrane-
traffi   cking steps in cells that lacked TRP-ML1 but that had 
    Figure 7.         LDL delivery to lysosomes is normal in TRP-ML  –  defi  cient cells.   Control or TRP-ML1 siRNA  –  treated (5 d) HeLa cells (A) or fi  broblasts 
(B) were preloaded for 12 h with Alexa Fluor 647  –  conjugated dextran. Cells were incubated with DiI-LDL on ice for 60 min and were subsequently 
chased in prewarmed media at 37  °  C for an additional 30 or 120 min. At the indicated time points, cells were fi  xed and processed for immunofl  uores-
cence. Delivery of DiI-LDL to lysosomes in cells was measured by quantifying the percent overlap between DiI-LDL and the preloaded Alexa Fluor 647  –
  dextran. Graphical representations of the quantifi  cations are shown (A and B, right) and are expressed as the percent overlap   ±   SEM for cells under 
each condition (  n   = 20). Bars, 10   μ  m.     1486 MEMBRANE TRAFFIC AND TURNOVER IN TRP-ML1  –  DEFICIENT CELLS   | Miedel et al. 
strongly against the biogenesis model for MLIV progression, 
which predicts that acute loss of TRP-ML1 function will re-
sult in a global defect in the delivery of both internalized lip-
ids and proteins to lysosomes. 
  The role of TRP-ML1 in lysosomal ion homeostasis is 
currently disputed. Increased accumulation of acridine or-
ange in MLIV fi  broblasts has previously been observed (  13  ), 
consistent with increased acidity of these organelles; how-
ever, quantitation of lysosomal pH in MLIV fi  broblasts by 
other groups has yielded discrepant results (  21, 39, 40  ). Simi-
lar to Pryor et al. (  21  ), we were unable to document any 
diff  erence in lysosomal pH between control and MLIV fi  bro-
blasts by fl  uorescence ratio imaging; however, our studies 
were compromised by the intense autofl  uorescence in MLIV 
lipid inclusions that has previously been reported (  41  ). How-
ever, we reproducibly observed that lysosomal pH in HeLa 
cells lacking functional TRP-ML1 was more acidic than con-
trol (a decrease of     1.12 pH units). In principle, this fi  nding 
is consistent with the metabolic model for MLIV pathogen-
esis, which postulates that the increased acidity of lysosomes 
disrupts lipid hydrolysis. 
Furthermore, colloidal gold internalized by fl  uid-phase endo-
cytosis could access inclusions in both isolated patient fi  bro-
blasts and in siRNA-treated cells, demonstrating that these 
organelles remain active components of the endocytic pathway. 
  Several studies have reported that the traffi   cking of fl  uo-
rescent conjugates of LacCer is hindered in MLIV fi  broblasts 
as well as in other lysosomal storage diseases (  13, 21, 23, 38  ). 
Consistent with these observations, we observed a similar de-
fect in LacCer handling in cells treated with TRP-ML1  –  spe-
cifi  c siRNA. However, we observed no diff  erence in the 
delivery of this lipid to lysosomes in control and TRP-ML1 
knockdown cells. Therefore, the altered traffi   cking of LacCer 
may represent an eff  ect on postlysosomal membrane traffi   c 
and/or lipid metabolism in cells after prolonged accumula-
tion of undigested materials. These results are consistent with 
a recent report by Thompson et al. (  43  ) suggesting that the 
primary defect in MLIV lipid handling may be the exit of in-
ternalized lipids from lysosomes. We found no eff  ect of acute 
TRP-ML1 knockdown on the rate of LDL delivery to lyso-
somes or on the degradation of both the lipid and protein 
components of this complex. Collectively, these data argue 
    Figure 8.         Degradation of LDL cholesterol is impaired in MLIV fi  broblasts.   (A) siRNA-transfected HeLa (5 d) or patient fi  broblasts were incubated 
on ice for 2 h with   125  I-apoB-LDL complexes. For control cells, 0.5   μ  M bafi  lomycin was added 30 min before LDL labeling and maintained in the culture 
medium throughout the experiment. After ligand binding, cells were washed and incubated in prewarmed medium. At the indicated time points, the me-
dium was collected and replaced, and cells were solubilized after the fi  nal time point. The rate of apoB degradation was determined by calculating the 
cumulative release of TCA-soluble counts into the medium, as described in Materials and methods. (B) siRNA-transfected HeLa (5 d) or patient fi  broblasts 
were labeled with medium containing 10% LPDS and [  14  C]CO  –  LDL complexes (50   μ  g/ml LDL protein) for 4 h at 37  °  C, washed, and incubated for 30 min at 
18  °  C in medium supplemented with 10% FBS. The time course was initiated by the addition of fresh culture medium supplemented with 10% LPDS at 
37  °  C. At the indicated times, the medium was collected and replaced. After the fi  nal time point, cells were harvested, and radioactivity was measured in 
both the medium and cell pellet. The cumulative percentage of preinternalized [  14  C]CO released into the medium at each time point was calculated as 
described in Materials and methods. The mean   ±   SEM of three experiments (two for bafi  lomycin A  1    –  treated samples) performed in triplicate is plotted in 
each panel. *, P = 0.032; and **, P   <   0.008 by using the Student  ’  s   t   test.   JEM VOL. 205, June 9, 2008 
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To generate the siRNA-resistant construct HA-ML1  R  , the codons encoding 
amino acids IQEC starting at position 281 of TRP-ML1 (targeted by siRNA 
no. 1) were mutated from CATCCAGGAGTG to TATTCAAGAATG to 
create siRNA resistance without aff  ecting the corresponding amino acid se-
quence. For knockdown of endogenous TRP-ML1, HeLa SS6 cells were 
plated in 24-well dishes and allowed to grow to     50  –  60% confl  uence. Cells 
were transfected with a nonspecifi  c control siRNA duplex (Thermo Fisher 
Scientifi  c) or TRP-ML1  –  specifi  c siRNA duplexes. For each individual well, 
3   μ  l of 20   μ  M siRNA oligonucleotide and 4.5   μ  l TransIT-TKO oligonucleo-
tide transfection reagent (Mirus) were used. Cells were harvested for protein 
concentration or Western blot analysis 1, 3, or 5 d after transfection. For cells 
transfected with siRNA twice over the 5-d knockdown period, 2 d after ini-
tial transfection, cells were replated onto 24-well plates, retransfected as de-
scribed the same day, and harvested for analysis either 24 or 72 h later. For 
knockdown of exogenously expressed HA epitope  –  tagged ML1 (HA-ML1) 
(  19, 20  ), cells were plated and transfected with siRNA as described. 24 h af-
ter siRNA transfection, cells were transiently transfected with cDNA encod-
ing HA-ML1 using Lipofectamine 2000 (Invitrogen), according to the 
manufacturer  ’  s protocol, and harvested for Western blot analysis 24 h later. 
Samples were immunoprecipitated and immunoblotted as previously de-
scribed (  19, 20  ). 
  Electron microscopy.     Cells grown on plastic dishes were fi  xed by a 30-
min incubation with a solution containing 2.5% glutaraldehyde in 0.1M 
Na-cacodylate, washed with 0.1M Na-cacodylate, postfi  xed with a solution 
containing 1% OsO4, washed with PBS, and stained en bloc for 30 min with 
2% uranyl acetate. After dehydration by immersion in 30  –  100% ethanol, the 
samples were embedded in resin by immersion in 30  –  100% resin/propylene 
oxide mixtures. Fixed samples were mounted on grids and analyzed with a 
transmission electron microscope (100CX; JEOL Ltd.). For immunostaining 
with lamp-1 antibodies, after fi  xation and freeze  –  thaw permeabilization of 
the membranes at   –  80  °  C in a cryoprotectant solution containing glycerol 
and sucrose, cells were blocked in BSA with goat serum, incubated over-
night with monoclonal anti  –  lamp-1 antibodies (Santa Cruz Biotechnology, 
Inc.), and rinsed, and biotinylated secondary antibodies were added. After an 
extensive wash, the samples were incubated with avidin  –  peroxidase com-
plexes for 30 min, followed by another wash. Next, 3,3    -diaminobenzidine 
and H  2  O  2   were added for 4  –  10 min and, after another wash, the samples un-
derwent secondary fi  xation with 1% OsO  4   for 1 h. This procedure yields the 
dark stain associated with lamp-1 immunoreactivity. 
  For colloidal gold uptake experiments, 10-nm gold particles were incu-
bated with gelatin and BSA (pH 5), to coat the particles. Next, the particles 
were washed and added to the cells for 1 h to load the endocytic pathway. 
After a 6  –  16-h chase, cells were fi  xed and processed for electron microscopy 
as described in the previous paragraph. 
  Measurement of lysosomal pH.     Determination of lysosomal pH was per-
formed as previously described (  50, 51  ). HeLa cells treated with siRNA for 
5 d were plated onto 0.17-mm     T live-cell cover glass dishes (Biotechs). 
12 h before the start of imaging, cells were loaded with 3 mg/ml each of 
FITC- and TMR-conjugated 10,000-kD dextrans (Invitrogen) to allow accu-
mulation in lysosomes. To measure pH diff  erences between cells, a standard 
curve was determined for each experiment. Before imaging for the standard 
curve, cells were rinsed once with MES buff  er (115 mM KCl, 5 mM NaCl, 
1.2 mM MgSO  4  , 25 mM MES) that had been calibrated using a pH meter 
(Accumet; Thermo Fisher Scientifi  c) to 3, 4, 5, 6, 7, or 8. After rinsing, the 
cells were imaged in the same buff  er supplemented with 10   μ  M nigericin 
and 10   μ  M monesin to equilibrate intracellular and extracellular pH. Experi-
mental dishes were imaged in DME without sodium bicarbonate. Images 
were taken using a microscope (IX81; Olympus) with a 60  ×   1.4 NA PlanApo 
oil-immersion objective. Pairs of images were captured from random fi  elds 
of cells using a spinning disc confocal system (Perkin Elmer). Images were 
acquired and analyzed with Metamorph software (MDS Analytical Technol-
ogies). For analysis, equivalent FITC and TMR images were subjected to a 
morphological fi  lter (Tophat) to remove background fl  uorescence. A binary 
  Previous groups have demonstrated defects in lipase han-
dling in MLIV fi  broblasts, including delayed deesterifi  cation 
of cholesterol esters and decreased lysosomal acid lipase activ-
ity (  13, 18  ). Consistent with this, we found that the release of 
free fatty acids from [  14  C]CO-labeled LDL was slowed in 
MLIV fi  broblasts. Surprisingly, however, we did not detect a 
defi  cit in cholesterol metabolism in siRNA-treated cells (after 
1, 5, or 12 d). 
  The apparently normal hydrolysis of LDL cholesterol 
upon acute loss of TRP-ML1 function demonstrates that the 
increased lysosomal acidity observed in these cells does not 
critically impair acid lipase activity. Rather, there appears to 
be a gradual eff  ect on lysosomal hydrolysis that manifests as a 
lag period between loss of TRP-ML1 function and the full 
elaboration of the MLIV disease phenotype. It is possible that 
a minor defi  cit in lipid hydrolysis that is undetectable early 
after TRP-ML1 loss has a cumulative eff  ect whose conse-
quences slowly develop as the disease progresses. Indeed, other 
lysosomal storage disease models such as Niemann-Pick type 
C (NPC) (  48, 49  ) teach us that a defect in a single compo-
nent of lysosomal machinery may sabotage processing of un-
related classes of lipids. NPC disease is caused by the mutation 
in either the late endosomal membrane protein NPC1 or the 
soluble lysosomal protein NPC2, and results in abnormal 
cholesterol transport along the late endocytic pathway. Simi-
lar to MLIV, NPC is caused by defective cholesterol traffi   ck-
ing rather than by a specifi  c enzymatic abnormality. Although 
the primary defect is in cholesterol transport, the accumula-
tion of other lipids, including sphingolipids, has also been 
demonstrated in NPC (  48  ). 
  In summary, our results suggest that TRP-ML1 does not 
directly regulate membrane traffi   c; thus, enzyme replacement 
therapies remain a potentially viable treatment option for MLIV. 
Future studies are needed to determine whether TRP-ML1 
plays an essential role in maintaining lysosomal ion homeo-
stasis directly so that replacement enzymes may be designed 
to operate in the unique environment of the TRP-ML1  – 
defi  cient lysosome. 
  MATERIALS AND METHODS 
  Cell lines and reagents.     HeLa SS6 cells were maintained in DME (Sigma-
Aldrich) supplemented with 10% FBS (Atlanta Biologicals) and 100   μ  g/ml 
penicillin/streptomycin (Invitrogen). Skin fi   broblasts from patients with 
MLIV (WG0909), a heterozygous relative (WG0987), and MLII (WG0229) 
were obtained from the Repository for Mutant Human Cell Strains. All skin 
fi  broblast cell lines were maintained in DME supplemented with 10% FBS 
and 100   μ  g/ml penicillin/streptomycin. All reagents were obtained from 
Sigma-Aldrich unless indicated otherwise. 
  siRNA-mediated knockdown of TRP-ML1.     Two double-stranded 
siRNAs targeting the human form of ML1 (TRP-ML1; available from Gen-
Bank/EMBL/DDBJ under accession no.   BC005149  ) were designed and 
synthesized using Invitrogen  ’  s proprietary BLOCK-iT RNAi protocol. The 
fi  rst TRP-ML1  –  specifi  c target sequence (ML1 siRNA no. 1) used was 
5    -CCCACATCCAGGAGTGTAA-3    , corresponding to nucleotides 959  –
  977 of the human TRP-ML1 mRNA. The second target sequence (ML1 
siRNA no. 2) used was 5    -CCGCTACCTGACCTTCTT-3    , correspond-
ing to nucleotides 1328  –  1345 of the human TRP-ML1 mRNA. All experi-
ments, unless otherwise noted, were performed used TRP-ML1 siRNA no. 1. 1488 MEMBRANE TRAFFIC AND TURNOVER IN TRP-ML1  –  DEFICIENT CELLS   | Miedel et al. 
Brown et al. (  54  ). 600   μ  g LDL (Biomedical Technologies, Inc.) and 120 mg 
LPDS (Biomedical Technologies, Inc.) were mixed in 0.15 M NaCl con-
taining 0.3 mM thiomersol, 1   μ  g/ml aprotinin, and 0.65 mM glutathione at 
a fi  nal volume of     1.6 ml. 5   μ  Ci [  14  C]CO (GE Healthcare) in denatured 
toluene solution was transferred to a 2.-ml conical tube and evaporated to 
dryness under a steady stream of nitrogen for     15 min, then resuspended in 
50   μ  l of absolute ethanol. The resuspended [  14  C]CO was incubated for     30 
min in a 37  °  C water bath with frequent vortexing to ensure complete resus-
pension. The LDL  –  LPDS was then added to the resuspended [  14  C]CO, and 
this mixture was incubated overnight at 37  °  C under nitrogen. The next day, 
the sample was transferred to a 0.5  –  3-ml Slide-A-Lyzer (10,000 kD) dialysis 
cassette (Thermo Fisher Scientifi  c) and dialyzed for 8  –  12 h at 4  °  C against 4 
liter of buff  er containing 0.15 M NaCl and 0.3 mM EDTA (pH 7). After di-
alysis, the solution was centrifuged in a benchtop microcentrifuge at 12,000 
rpm for 5 min. The supernatant solution was collected, supplemented with 
0.5% human serum albumin, and stored for up to 3 wk at 4  °  C. 
  Degradation of [  14  C]CO  –  LDL.     [  14  C]CO  –  LDL degradation was per-
formed essentially as previously described by Groener et al. (  44  ), with slight 
modifi  cation. HeLa SS6 cells or human skin fi  broblasts were cultured in 
DME supplemented with 10% FBS and 100   μ  g/ml penicillin/streptomycin. 
Cells were plated in 12-well plates at     50% confl  uence. 48h before the start 
of an experiment, cells were preincubated with DME supplemented with 
10% LPDS to up-regulate cell-surface expression of the LDL receptor. Cells 
were then incubated with 0.4 ml DME containing 10% LPDS and [  14  C]CO  –
  LDL (50   μ  g/ml LDL protein) for 4h at 37  °  C. The labeling medium was re-
moved, and cells were washed with PBS and incubated for 30 min at 18  °  C 
in DME supplemented with 10% FBS. The experiment was initiated by the 
addition of fresh DME supplemented with 10% LPDS at 37  °  C to scavenge 
the released free fatty acids (  44  ). Where indicated, 0.5   μ  M bafi  lomycin A  1   
(Sigma-Aldrich), was added to culture medium 30 min before labeling and 
maintained throughout the time course. At various times (0.5  –  4 h), the me-
dium was collected and replaced. At the end of the time course, cells were 
harvested in buff  er containing 50 mM Tris-HCl (pH 7.4) and 1% Tx-100. 
Radioactivity was measured in both the medium and the cell pellet by liquid 
scintillation counting. The percentage of [  14  C]CO  –  LDL degraded was cal-
culated as the amount of radioactivity present in the medium divided by the 
total radioactivity present in the medium and cell pellet. 
  Degradation of   125  I-apoB-LDL.     HeLa SS6 cells or human skin fi  broblasts 
were cultured in DME supplemented with 10% FBS and 100   μ  g/ml penicil-
lin/streptomycin. Cells were plated in six-well plates at     50% confl  uence. 
48 h before the start of an experiment, cells were preincubated with DME 
supplemented with 10% LPDS to up-regulate cell-surface expression of the 
LDL receptor. Cells were incubated in DME supplemented with   125  I-apoB-
LDL (25   μ  g/ml LDL protein at 50   μ  Ci/ml; Biomedical Technologies, Inc.) 
on ice for 2h (0.6 ml). Cells were extensively washed in DME containing 
BSA for three 10-mim periods. For control samples, 0.5   μ  M bafi  lomycin A  1   
was added 30 min before LDL labeling and maintained throughout the time 
course. At the start of the experiment, cells were incubated with 0.6 ml of 
prewarmed DME per well at 37  °  C. At various times (10  –  180 min), the me-
dium was collected from cells and replaced. After the time course was com-
pleted, the cells were solubilized with buff  er containing 50 mM Tris-HCl 
(pH 7.4) and 1% Tx-100 for 15 min. After solubilization, TCA was added to 
the medium collected over the time course and to the solubilized cells (fi  nal 
concentration = 10% [vol/vol]). The samples were incubated on ice for 20 min 
and centrifuged at maximum speed in a microcentrifuge at 4  °  C for 15 min. 
Radioactivity in the corresponding supernatants and pellets was counted using 
a      counter (PerkinElmer). The rate of   125  I-apoB-LDL degradation was de-
termined by calculating the cumulative release of TCA-soluble counts into 
the medium over the experimental time course. 
  This work was supported by an ML4 Foundation grant (to K. Kiselyov), by a seed 
money award from the Pittsburgh Life Science Greenhouse (to K. Kiselyov), by 
National Institutes of Health grant DK54407 (to O.A. Weisz), by an American 
mask was applied so that only matched spots from each image were com-
pared. After applying a threshold, the total gray value for each image was re-
corded for both channels, and the TMR/FITC ratio was determined. 
TMR/FITC ratios were plotted against pH values, and curves were fi  tted us-
ing linear regression analysis. At least 20 images were analyzed for each condi-
tion in four independent experiments. The Student  ’  s   t   test was used to 
determine statistical signifi  cance. 
  LacCer traffi   c.     To examine LacCer traffi   cking at long chase times, HeLa 
cells were labeled with 5   μ  M LacCer complexed to BSA in serum-free DME 
for 60 min at 37  °  C. Cells were gently washed three times with PBS and incu-
bated with DME plus 10% FCS for 5 h at 37  °  C. After chase, cell-surface Lac-
Cer was back-extracted by washing cells for 30 min in DME without 
bicarbonate supplemented with 2% (wt/vol) fatty acid  –  free BSA at 4  °  C. Cells 
were washed briefl  y with PBS, and images were acquired in DME without 
bicarbonate at 20  °  C. Images were acquired using the Olympus IX81 equipped 
with a spinning disc confocal microscope system (UltraVIEW; PerkinElmer). 
Cells were imaged using a 60  ×   objective, and the LacCer was excited using a 
488-nm laser, whereas the dextran was excited using a 647-nm laser. These 
two excitation fi  lters were used to account for the aggregation-dependent shift 
in red fl  uorescence that is characteristic of the BODIPY fl  uorophore. Under 
these experimental conditions, little red LacCer fl  uorescence was observed, so 
LacCer images in   Figs. 5 and 6   were acquired using only the 488-nm laser. 
  For shorter experiments examining lysosomal delivery kinetics, HeLa 
cells were loaded with LacCer (Invitrogen) and analyzed as before (  13  ). After 
loading and chase, cells were incubated with the lysosomal marker Lyso-
Tracker Red (Invitrogen) and confocal images were taken. The images were 
analyzed using the RGB colocalization add-in to ImageJ (available at http://
rsb.info.nih.gov/ij/), as previously described (  13, 52  ). In each image, the 
percentage of LacCer in lysosomes (  %laccer  Lys    ) was estimated by dividing the 
number of pixels contained within the area of overlap between LacCer and 
LysoTracker stains (  N  over    ) by the number of pixels covered by the LacCer 
staining pattern (  N  laccer    ):   %laccer  Lys     = 100   ×     N  over  /N  laccer    . To estimate   N  laccer    , the 
threshold settings of the LacCer image were adjusted to remove the signal 
from the cytoplasm and binarized by assigning 1 to each LacCer-positive 
pixel and 0 to LacCer-negative pixels.   N  laccer    , the number of nonzero pixels, 
was calculated using the analysis function of ImageJ. Next, to calculate   N  over    , 
red (LysoTracker), green (LacCer), and blue (null) images of the same fi  eld of 
view were merged, and the resulting RGB image was subjected to the RGB 
colocalization algorithm, yielding a single binary image in which each pixel 
positive for both green (LacCer) and red (LysoTracker) signals has a value of 
1 and each pixel negative for either green or red signals has a value of 0.   N  over     
is the number of pixels with nonzero values. 
  DiI-LDL labeling.     48 h before imaging, cells were plated onto coverslips 
and preincubated in DME supplemented with 10% LPDS to up-regulate 
LDL receptor surface expression. Alexa Fluor 647  –  conjugated dextran (Invi-
trogen) was preaccumulated in lysosomes during a 12-h incubation before the 
start of the experiment. The next day, cells were incubated with 20   μ  g/ml 
DiI-LDL (Invitrogen) on ice for 60 min to allow LDL binding. Cells were 
subsequently washed in PBS and chased in fresh DME for either 30 or 120 
min at 37  °  C. At the end of the time course, cells were fi  xed in 3.7% parafor-
maldehyde (Sigma-Aldrich) solution diluted in PBS for 10 min and mounted 
for image analysis. Confocal imaging was performed on an Olympus IX81 
equipped with an UltraVIEW spinning disc confocal head, and an argon  –  ion, 
argon  –  krypton, and helium  –  cadmium laser combiner. Images were acquired 
with a 100  ×   plan-apochromat objective (NA 1.4) and the appropriate fi  lter 
combination. The extent of colocalization between Alexa Fluor 647  –  dextran 
and DiI-LDL  –  positive compartments was determined using image analysis 
software (Metamorph; MDS Analytical Technologies). The TIFF images 
were imported into Photoshop (Adobe) to adjust contrast and image size. 
  Preparation of [  14  C]CO  –  LDL complexes.     In vitro preparation of cho-
lesteryl ester  –  radiolabeled lipoproteins was performed according to a modi-
fi  ed version of the methods previously described by Terpstra et al. (  53  ) and JEM VOL. 205, June 9, 2008 
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